Objectives: Besifloxacin is a new fluoroquinolone in development for ocular use. We investigated its mode of action and resistance in two major ocular pathogens, Streptococcus pneumoniae and Staphylococcus aureus, and in the reference species Escherichia coli.
Introduction
Fluoroquinolones have been developed over the last 20 years with a recent focus on new compounds exhibiting enhanced activity against Gram-positive bacteria, mainly pneumococci (Streptococcus pneumoniae) and staphylococci. 1 Fluoroquinolones have been shown to target DNA gyrase and topoisomerase IV, the two type II bacterial topoisomerases.
2 -4 DNA gyrase catalyses negative supercoiling of DNA, whereas topoisomerase IV is specialized for decatenation. Both enzymes cleave double-stranded DNA, an action specific to type II topoisomerases. In vitro assays that measure the effects of quinolones on their targets determine: (i) inhibition of DNA supercoiling by DNA gyrase; (ii) inhibition of decatenation by topoisomerase IV; and (iii) stabilization of DNA cleavable complexes for both enzymes. 5, 6 The question of the primacy of one or the other enzyme as a drug target has arisen since the discovery that topoisomerase IV can be a quinolone target. 4 Primacy is usually determined by in vitro selection experiments in which a resistance mutation is observed first in one of the two genes of the primary target and gene mutations in the secondary target are only observed subsequently. 7, 8 The new fluoroquinolone besifloxacin ( previously known as BOL-303224-A or SS734, see Figure 1 ) has exhibited potent in vitro antibacterial activity against S. pneumoniae and Staphylococcus aureus in preliminary studies. Besifloxacin is currently in late stage clinical development as a topical formulation for treatment of ocular infections. 9 To gain insight into its mode of action, we investigated the topoisomerase targeting activity of besifloxacin in these two species that are major bacterial pathogens involved in ocular infections. Escherichia coli was tested in parallel as a reference bacterial species for quinolone action and resistance. Our objectives were: (i) to measure besifloxacin's effect on its putative cellular targets, DNA gyrase and topoisomerase IV; and (ii) to define the primary and secondary intracellular targets of besifloxacin. Ciprofloxacin and moxifloxacin were also tested as reference fluoroquinolone controls.
Materials and methods
Strains and antibacterial agents E. coli strain KL16, S. aureus strain ATCC 15752 (www. lgcpromochem-atcc.com) and S. pneumoniae strain 7785 were the parental strains for the mutant selection experiments already used in previous studies. 10 -12 Strains with defined mutations in the topoisomerase genes listed in Tables 2, 4 and 5 were derived from the parental strains and have been characterized with respect to their type II topoisomerase (gyrA, gyrB, parC and parE) genotype. 10 -16 Besifloxacin was provided by Bausch and Lomb/Chauvin laboratories (Montpellier, France), and moxifloxacin and ciprofloxacin were from Bayer Pharma (Puteaux, France). MICs of besifloxacin, ciprofloxacin and moxifloxacin were determined by the reference agar dilution method.
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Topoisomerase assays
Recombinant subunits of S. pneumoniae DNA gyrase and topoisomerase IV were produced as histidine-tagged recombinant proteins and purified from E. coli lysates using nickel columns as described previously.
18 Recombinant E. coli gyrase and topoisomerase IV were obtained from John Innes Enterprises, Norwich, UK. 19 As described previously, the enzymatic inhibition of topoisomerases from S. pneumoniae and E. coli was assessed by measuring the inhibitory concentrations (IC 50 in mM) of besifloxacin, ciprofloxacin and moxifloxacin for plasmid supercoiling mediated by DNA gyrase and decatenation of kinetoplast DNA catalysed by topoisomerase IV. 5, 18, 20 For each enzyme, the ability of a quinolone to mediate double-stranded DNA breakage was tested as described previously using DNA cleavable complex assays and was assessed by measuring the concentration that induced 25% of the maximum DNA cleavage (CC 25 in mM).
18,21
Inhibition of supercoiling or decatenation enzyme activities and stimulation of DNA cleavage were determined in three independent experiments for each of the type II topoisomerases.
In vitro selection of resistant mutants
Mutant selection experiments were carried out as described previously. 11, 22 Briefly, inocula of ca. 10 9 bacteria per plate were spread on Mueller-Hinton (MH) agar for E. coli and S. aureus, or on 10% blood-MH agar for S. pneumoniae containing increasing concentrations of besifloxacin at 2-, 4-, 8-, 16-and 32-fold the MIC for the parental strain. As a control, similar experiments were performed in parallel for ciprofloxacin for the three species and in addition for moxifloxacin in the case of S. pneumoniae. Incubation was at 378C aerobically for 24 -48 h. Inoculum size was determined by counting colonies from dilutions plated on agar without quinolones. Colonies appearing on drug-containing plates were subsequently grown in drug-free medium to assess the stability of resistant isolates. Results from initial besifloxacin mutant selection experiments were confirmed by a second round of independent selection experiments that yielded comparable results. Randomly chosen colonies from independent agar selection plates were purified on drug-free agar media, and resistant isolates were characterized by MIC determinations of besifloxacin plus comparator quinolones and by screening for quinolone resistance-determining region (QRDR) topoisomerase mutations as detailed below.
Screening for mutations in the QRDRs of gyrA, gyrB, parC and parE PCR primers were chosen from previous studies on topoisomerase mutants of E. coli, S. aureus and S. pneumoniae, in order to amplify a fragment encompassing the QRDR as defined for each gene. 11, 16, 23 Total DNA was released from mutants by thermal shock. PCR amplified fragments were purified using the Montage PCR Kit (Millipore) and sequenced with the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied BioSystems) on an ABI PRISM 3100 Sequencer (Applied BioSystems). Sequences were analysed with Chromas and BioEdit software.
Results
Topoisomerase targeting of besifloxacin in S. pneumoniae Table 1 summarizes IC 50 and CC 25 values determined from the enzymatic activity experiments (quinolone-mediated enzyme inhibition and formation of cleavable complexes) for besifloxacin, ciprofloxacin and moxifloxacin using purified recombinant S. pneumoniae gyrase and topoisomerase IV enzymes. IC 50 IC 50 values for both S. pneumoniae enzymes were not significantly different. Likewise, besifloxacin CC 25 values for both enzymes were nearly equivalent and also matched the IC 50 values. Against S. pneumoniae DNA gyrase, the besifloxacin IC 50 was 15-fold lower than that for ciprofloxacin and 4-to 8-fold lower than that for moxifloxacin. Besifloxacin was 5-fold more potent than ciprofloxacin and 2-fold more potent than moxifloxacin against S. pneumoniae topoisomerase IV. These results indicate that in vitro activity of besifloxacin is at least equal to, or higher than, that of ciprofloxacin and moxifloxacin comparators, with nearly equipotent activity against both essential S. pneumoniae type II topoisomerases. Table 2 summarizes MICs of besifloxacin and both comparator quinolones for S. pneumoniae strains with previously characterized topoisomerase mutations. MICs for the ciprofloxacin and moxifloxacin controls were identical or within 2-fold of those determined previously for the same mutant strains. 11, 12, 26 The presence of a parC mutation in S. pneumoniae increased the besifloxacin MIC by 2-fold or less, whereas a mutation in gyrA increased the MIC by 4-fold. These results show that single mutations in either gyrA or parC have similar 2-to 4-fold effects on MIC values, suggesting that neither gene is a strongly preferred target for spontaneous resistance development. As expected for a quinolone, besifloxacin MICs for various parC -gyrA double mutants were further elevated relative to the wild-type fully susceptible parent strain: 8-fold besifloxacin MIC increases were observed for all three parC -gyrA double mutant variants (Table 2) . However, this 8-fold increase in besifloxacin MICs was less than the corresponding 16-to 32-fold increases measured for the comparator quinolones.
Selection of resistant S. pneumoniae mutants was conducted on agar plates supplemented with besifloxacin for two successive steps of selection (two independent experiments for the first step), including parallel selections on ciprofloxacin control plates during the first step. In both first-step agar selection experiments, no S. pneumoniae mutants were recovered at 4-fold the besifloxacin MIC. Instead, viable mutants could only be obtained on agar plates at 2-fold besifloxacin MICs. Moreover, as shown in Table 3 , the proportion of resistant mutants on 2-fold besifloxacin MIC plates (5 -8.6Â10
29 ) was nearly two orders of magnitude lower than the corresponding proportion of resistant mutants recovered on 2-fold ciprofloxacin MIC plates (1.6Â10 27 ). Consistent with previous reports, parC mutants selected on ciprofloxacin resulted in changes in codons 79 and 83 (data not shown, numbering according to S. pneumoniae proteins). 11, 27, 28 In contrast, sequencing of the topoisomerase QRDRs for 10 of 10 first-step mutants selected on 2-fold besifloxacin MIC revealed only gyrA mutations, with corresponding amino acid substitutions at codon 81 (S81F, S81Y) or 85 (E85K) Besifloxacin mode of action and resistance (S. pneumoniae numbering). These GyrA S81F, S81Y or E85K mutants were then used as parental strains in a second round of besifloxacin selection. All 10 of the resulting besifloxacin second-step selection mutants that were sequenced carried either parC (S79F or S79Y) or parE (E474K) second-step mutations in addition to the first-step gyrA mutations. Besifloxacin MICs for all the first-step gyrA mutants increased by only 2-to 4-fold (modal MIC of 0.5 mg/L) and increased further by only 2-fold (modal MIC of 1 mg/L) in the second-step mutants containing various gyrA -parC or gyrA -parE double mutations. These step selection findings are thus consistent with the previous MIC results determined for defined fluoroquinolone-resistant mutants ( Table 2 ). The agar selection results therefore indicate that according to the definition of primacy targeting, 7 DNA gyrase has the primacy for besifloxacin targeting in S. pneumoniae and topoisomerase IV is the secondary target. However, neither the primary gyrA mutations nor the secondary parC mutations result in substantially elevated MICs of besifloxacin.
In summary, for S. pneumoniae, the enzyme assay results were in favour of a slight preference for topoisomerase IV targeting, whereas the MIC results and in vitro mutant selection results favoured the DNA gyrase as the principal target. This may be due to nearly equipotent targeting of both these essential type II topoisomerases, which is further supported by very similar 2-to 4-fold besifloxacin MIC increases associated with various defined mutations in either the gyrA or the parC genes.
Primacy of besifloxacin targeting in S. aureus
Stepwise mutant selection of S. aureus mutants resistant to fluoroquinolones was performed by the same method used for S. pneumoniae. Resistant mutants selected with ciprofloxacin controls were obtained at proportions similar to those reported previously (Table 3) . 8 Similar to the S. pneumoniae findings, two independent first-step mutant selection experiments (each with inocula of 1 -3Â10 9 cells per selection plate) yielded no viable S. aureus colonies on 4-fold besifloxacin MIC agar
plates. An attempt to use higher inocula of 10 10 did not lead to clear results (faint growth on besifloxacin containing agar) but without mutant selection. A total of only 12 S. aureus colonies were isolated on 2-fold besifloxacin MIC plates from the experiments. Only 10 of these 12 colonies showed decreased besifloxacin susceptibility, with besifloxacin MICs that were 2-to 8-fold higher than the parental strain MIC of 0.03 mg/L. Also, none of the 10 mutants selected on 2-fold besifloxacin MIC agar had mutations in the classical QRDRs of gyrA, gyrB, parC or parE. Second-step selections were then attempted with two different first-step mutants selected on 2-fold besifloxacin MIC plates. However, no viable second-step mutants were obtained after two attempts. These results suggest that direct selection of besifloxacin-resistant S. aureus mutants with MICs above 0.25 mg/L occurs at a very low frequency (i.e. ,10 211 ). Consistent with previous reports, quinolone-resistant S. aureus mutants selected on ciprofloxacin control plates had mutations at codons 80 and 84 in parC. 8 To further investigate which topoisomerase mutations were selected in the presence of besifloxacin, a multiple step selection experiment was conducted in liquid medium using MH broth. Cultures were serially passaged in broth with besifloxacin concentrations ranging from 0.5-fold MIC (0.015 mg/L) to 64-fold MIC (2 mg/L). Surviving cells were then plated on besifloxacin agar and the QRDRs of gyrA, gyrB, parC and parE of these isolates were sequenced. Initial mutants were chosen from two independent broth cultures at a besifloxacin concentration of 0.5 mg/ L. Each of the two mutant strains had a gyrA mutation at codon 84 leading to the novel S84A substitution (S. aureus numbering system). Besifloxacin MICs for these two mutants from serial liquid passage were 0.12 and 0.5 mg/L; whereas the corresponding ciprofloxacin MICs were 2 and 0.5 mg/L and moxifloxacin MICs were 8 and 0.5 mg/L, respectively. After further serial passage of these cultures in besifloxacin supplemented broth, the S84A gyrA mutation was found together with a parC mutation at either codon 80 (S80Y) or at codon 84 (E84K), with a final besifloxacin MICs of 4 mg/L. This finding after multiple steps of proportion at 4Â MIC -1.6Â10
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(1), first experiment; (2), second experiment; -, no data.
selection in besifloxacin supplemented broth suggests that DNA gyrase is probably the primary target for besifloxacin in S. aureus. However, the failure to recover any viable colonies on 4-fold besifloxacin MIC plates after two agar selection steps, plus the isolation of only gyrA mutants after multiple steps of serial passage in broth containing besifloxacin strongly suggest that .2-fold increases in S. aureus besifloxacin MICs require mutations at other sites of topoisomerase genes or in other genes. The besifloxacin MICs determined for S. aureus mutants with defined topoisomerase mutations were consistently lower than those for ciprofloxacin and moxifloxacin (Table 4) . Regardless of the identity of the parC mutation, besifloxacin MICs increased only 2-fold between the parental strain and various defined parC QRDR mutants. In contrast, MICs of ciprofloxacin and moxifloxacin increased by 4-to 8-fold in defined parC single mutants. When S. aureus strains carried mutations in both topoisomerase targets (a parC mutation combined with either gyrA or gyrB DNA gyrase mutations), besifloxacin MICs increased by 8-fold. However, even in these double mutants, besifloxacin MIC values never exceeded 0.5 mg/L, which was 128-fold lower than the ciprofloxacin MIC (64 mg/L) and 4-fold lower than the moxifloxacin MIC (2 mg/L).
Besifloxacin mode of action and resistance in E. coli
To investigate if besifloxacin activity against Gram-negative bacteria is also mediated by inhibition of type II topoisomerases, biochemical mechanism and genetic resistance experiments were also performed with E. coli, the reference bacterium for quinolone action and resistance. 7 As summarized in Table 1 , besifloxacin and the control quinolones ciprofloxacin and moxifloxacin showed similar biochemical activities against E. coli DNA gyrase (IC 50 range 1.0-2.5 mM; CC 25 range 0.1 -0.2 mM) and topoisomerase IV (IC 50 range 20 -25 mM; CC 25 range 1.5 -2.3 mM), indicating that the enzymatic inhibition and cleavable complex profile of besifloxacin is comparable to comparator quinolones with Gram-negative activity. Interestingly, the comparison between the inhibition of E. coli and S. pneumoniae topoisomerases revealed that besifloxacin is one of the rare quinolones with low IC 50 values (2.5 mM) for both E. coli and S. pneumoniae DNA gyrases.
Selection of E. coli mutants with elevated besifloxacin MICs identified DNA gyrase as the primary target since gyrase gene mutants were observed at the first step, and topoisomerase IV gene mutants were observed only at the second step of selection. Single gyrA mutations (S83L, D87Y or G81D; E. coli numbering system) were observed in 3 of 10 randomly chosen first-step mutants. In the remaining seven mutants, no mutations were observed either in parC or in parE. In addition, S83L or G81D gyrA mutations were observed in second-step mutants selected from the seven first-step mutants that had been devoid of mutations in the topoisomerase genes QRDR, showing that again gyrase gene mutation was observed when no topoisomerase IV gene mutations were shown. The unique gyrA mutation leading to the G81D substitution was observed at each besifloxacin selection step. Whereas besifloxacin MICs for defined E. coli topoisomerase mutants were 2-to 16-fold higher than those of ciprofloxacin, they were similar to those of moxifloxacin except for the gyrB mutants and the gyrAG81D mutant (Table 5) . For all three fluoroquinolones tested, substantially elevated MICs (.4 mg/L) were observed for E. coli strains with defined quinolone-resistance mutations in both DNA gyrase and topoisomerase IV genes.
Discussion
Besifloxacin is a new fluoroquinolone in late stage clinical development for topical treatment of ocular infections. Here, we investigated the activity of besifloxacin against bacterial DNA gyrase and topoisomerase IV both in vivo and in vitro with purified enzymes. S. pneumoniae and S. aureus were tested as the most prevalent Gram-positive pathogens in ocular infections, 29, 30 while E. coli was chosen as the Gram-negative reference bacterium for evaluating the quinolone mechanism of action and resistance. We showed that besifloxacin is a potent inhibitor of both DNA gyrase and topoisomerase IV in vitro and is equally active against DNA gyrases from S. pneumoniae and E. coli. Spontaneous resistance development experiments reported here indicate that the primacy of besifloxacin targeting in all three species was for DNA gyrase. However, the combined biochemical and genetic mechanism studies presented here also indicate that besifloxacin acts via a relatively balanced targeting towards both DNA gyrase and topoisomerase IV in S. aureus and in S. pneumoniae. Mutant selection studies conducted previously in S. pneumoniae showed that the primary target for classic fluoroquinolones, such as ciprofloxacin and ofloxacin, is topoisomerase IV. In contrast, newer fluoroquinolones such as moxifloxacin, sparfloxacin, grepafloxacin, gatifloxacin and gemifloxacin primarily target DNA gyrase. 11, 12, 31, 32 We have shown here that the primary target of besifloxacin is also DNA gyrase. Alovero et al. 24 demonstrated that the structure of the quinolone itself determines which type II topoisomerase is the preferred target. A large group at the C-7 position of the quinolone favours DNA gyrase as the target and the substituent at positions C-5 and C-8 also has a role in target specificity. 31, 33 The structure of besifloxacin is defined by a bulky 3-aminohexahydro-1H-azepine ring at C-7 and a chlorine group at C-8 (Figure 1) , two features that would contribute to targeting DNA gyrase. Although gyrase is the primary target in first-step selection experiments, besifloxacin MICs increased only 4-fold in gyrA mutants compared with the parental strain. This finding is consistent with other fluoroquinolones that exhibit dual targeting. 34, 35 This suggests that in gyrA mutants of S. pneumoniae, besifloxacin targets topoisomerase IV, but since the concentration needed to achieve topoisomerase IV inhibition is also low, the MICs for gyrA mutants do not increase substantially. The overall results of the besifloxacin studies are thus consistent with nearly balanced targeting of both DNA gyrase and topoisomerase IV in S. pneumoniae. The seeming disparity between the greater quinolone sensitivity of topoisomerase IV over gyrase in vitro but the selection by quinolones of gyrA mutants in vivo is well recognized and possible explanations have been much discussed in the literature. 18, 26 In contrast to S. pneumoniae, topoisomerase IV is the primary target for most fluoroquinolones in S. aureus, even for the newer compounds, such as moxifloxacin, gatifloxacin and gemifloxacin. 8, 36 For example, spontaneous mutants isolated following selection on these drugs contained alterations in the parC or parE genes. 37 -39 However, mutants selected in vitro by these newer quinolones are usually obtained at a lower frequency than with ciprofloxacin, and the mutations within the parC or parE genes often map to regions outside the classical QRDRs. 37, 39, 40 For some of the latest compounds, initial mutations have been detected in gyrA or parC at equal frequencies, and dual targeting has been suggested. 40, 41 However, in our study, no viable S. aureus isolates resistant to besifloxacin were obtained after two steps of selection on 4-fold besifloxacin MIC agar, which contrasts with the ready selection of viable resistant mutants on ciprofloxacin control plates. This low rate of emergence of resistant strains would be expected in the case of targeting both type II topoisomerases at similar concentrations since two mutations affecting DNA gyrase and topoisomerase IV are required to confer a significant level of resistance, and the probability that they occur simultaneously is very low. Besifloxacin-resistant mutants of S. aureus were eventually isolated by selection through multiple steps in liquid medium, which may suggest that compensatory mutations are mandatory for stability of the occurrence of type II topoisomerase mutation. The gyrA mutation identified from these serial selections in broth culture was indeed a novel S84A substitution. It is similar to the S83A substitution in E. coli GyrA, previously shown to effectively decrease quinolone binding to the DNA gyrase and that also confers only a low level of resistance. 42 The absence of classical QRDR mutations in S. aureus mutants warrants future investigation in topoisomerase genes (the mutants we investigated had no mutations at the 5 0 ends of gyrB, parE and gyrA) and other loci, and this suggests that the site of topoisomerase interaction may slightly differ from that of the other fluoroquinolones.
Our mutant selection experiments confirm that in E. coli, the primary target for besifloxacin was DNA gyrase as described for all quinolones tested so far. 7, 43, 44 However, one of the observed gyrA mutations, which is known to confer resistance to fluoroquinolones but susceptibility to nalidixic acid, was of a rare type (G81D). The significance of this mutation in quinolone-resistant clinical strains remains to be determined. 16, 45 As noted earlier for S. aureus agar selections, we further note that the absence of classical QRDR mutations in 7 of 10 E. coli mutants initially recovered from besifloxacin selection plates warrants future investigation in order to determine whether other mechanisms involving permeability defect and efflux occur mainly in besifloxacin resistance.
A supplemental experimental approach to determine the significance of a specific mutation is to compare strains with defined mutations in the topoisomerase genes with their parental strains. The increase in MIC between the parental strain and the mutant measures the effect of the mutation. Although the absolute MIC values of besifloxacin were higher than those of ciprofloxacin for all the E. coli strains tested, the relative MIC increases between gyrA mutants and the parental strain were lower for besifloxacin than for ciprofloxacin and were similar to corresponding MIC increases for moxifloxacin. 10, 13 A combination of gyrase mutations with topoisomerase IV mutations led to a further increase in besifloxacin MICs, as was observed for other fluoroquinolones in this and other studies.
14,46 -48 In S. aureus, besifloxacin MICs increased only 2-fold for parC mutants (S80F, S80Y or E84K), which indicates that the DNA gyrase might be the alternative target even at low concentrations. Although besifloxacin MICs increased from 8-to 16-fold in gyrA -parC double mutants, the corresponding MICs of ciprofloxacin and moxifloxacin controls increased by 16-to 64-fold. Moreover, the absolute besifloxacin MIC value was lower than that of other fluoroquinolones such as gatifloxacin, gemifloxacin and moxifloxacin. 37, 38, 41 In contrast, besifloxacin MIC values for defined gyrA -parC double mutants of S. pneumoniae and S. aureus did not exceed 1 mg/L, thus suggesting that this concentration is sufficient to simultaneously inhibit quinoloneresistant DNA gyrase and quinolone-resistant topoisomerase IV.
Quinolones are known to act through inhibition and cleaved complex stimulation against DNA gyrase (the bacterial topoisomerase present in all bacteria) and against topoisomerase IV (a principal target in Gram-positive pathogens). 49 DNA-cleavage stimulation experiments have been correlated with killing activity and with MICs in Gram-negative species. Besifloxacin inhibition of bacterial topoisomerases was in the same range as other new fluoroquinolones, and besifloxacin-mediated DNAcleavage induction was particularly pronounced against both bacterial enzymes. These results confirm that besifloxacin, like other quinolones, acts through DNA gyrase and topoisomerase IV inhibition and stimulation of cleavage complexes.
In E. coli, quinolones are typically more active against DNA gyrase than against topoisomerase IV, with DNA gyrase IC 50 values ranging from 0.5 to 10 mM, while topoisomerase IV IC 50 values are usually $10-fold higher. 3, 20, 43 However, in S. pneumoniae, investigators have noted a reverse pattern such that quinolones are instead more active against topoisomerase IV (IC 50 values of 1 to 40 mM) than gyrase (IC 50 values up to 400 mM). 26, 49, 50 The lowest IC 50 values reported for S. pneumoniae DNA gyrase were for clinafloxacin and sitafloxacin (2.5-5 mM). 50, 51 When IC 50 values were measured within the same laboratory, it appeared that gemifloxacin, clinafloxacin and sitafloxacin were 10-fold more active against topoisomerase IV, and 20-to 50-fold more potent against DNA gyrase, than ciprofloxacin, levofloxacin and sparfloxacin, and 4-to 5-fold more potent than moxifloxacin and gatifloxacin. This increased potency was also noted for besifloxacin in the current study since its IC 50 values are 5-and 20-fold lower against topoisomerase IV and DNA gyrase, respectively, than those of ciprofloxacin, and 2-to 4-fold lower than those of moxifloxacin. Fluoroquinolones with similar IC 50 values against both S. pneumoniae DNA gyrase and topoisomerase IV are rare and include clinafloxacin, gemifloxacin, sitafloxacin and now besifloxacin. 26, 50 Based on the known quinolone mode of action, these latter new fluoroquinolones can be described as dual targeting inhibitors within the bacterial cell (i.e. simultaneous activity against both topoisomerases), or even as relatively balanced targeting inhibitors as we describe for besifloxacin.
